Acelyrin (SLRN) Competitors

Acelyrin (NASDAQ:SLRN) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Does the MarketBeat Community prefer SLRN or WVE?

Wave Life Sciences received 351 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 67.84% of users gave Wave Life Sciences an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.

Company	Underperform	Outperform
Acelyrin	Outperform Votes 16 55.17%	Underperform Votes 13 44.83%
Wave Life Sciences	Outperform Votes 367 67.84%	Underperform Votes 174 32.16%

Do analysts rate SLRN or WVE?

Acelyrin presently has a consensus target price of $9.60, indicating a potential upside of 336.36%. Wave Life Sciences has a consensus target price of $22.18, indicating a potential upside of 274.69%. Given Acelyrin's higher possible upside, equities analysts clearly believe Acelyrin is more favorable than Wave Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acelyrin	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Wave Life Sciences	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is SLRN or WVE more profitable?

Acelyrin has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Acelyrin's return on equity of -44.12% beat Wave Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acelyrin	N/A	-44.12%	-39.02%
Wave Life Sciences	-66.50%	-280.57%	-52.90%

Which has better valuation & earnings, SLRN or WVE?

Wave Life Sciences has higher revenue and earnings than Acelyrin. Wave Life Sciences is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acelyrin	N/A	N/A	-$381.64M	-$2.50	-0.88
Wave Life Sciences	$108.30M	8.39	-$57.51M	-$0.79	-7.49

Does the media prefer SLRN or WVE?

In the previous week, Wave Life Sciences had 16 more articles in the media than Acelyrin. MarketBeat recorded 20 mentions for Wave Life Sciences and 4 mentions for Acelyrin. Acelyrin's average media sentiment score of 1.07 beat Wave Life Sciences' score of 0.73 indicating that Acelyrin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acelyrin	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Wave Life Sciences	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, SLRN or WVE?

Acelyrin has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.93, suggesting that its stock price is 193% less volatile than the S&P 500.

Do institutionals and insiders believe in SLRN or WVE?

87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by company insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Wave Life Sciences beats Acelyrin on 11 of the 18 factors compared between the two stocks.